Anticoagulation: Difference between revisions

Revision as of 05:54, 25 January 2008

The metadata subpage is missing. You can start it via filling in this form or by following the instructions that come up after clicking on the [show] link to the right.

Do you see this on PREVIEW? then SAVE! before following a link.

To find out more about the use of metadata for the management of Citizendium pages, see CZ:Metadata.

You may see this box for one of two reasons. Either:

A - New page has been created, or subpages template was added to an existing page

B - Cluster move is in progress

Click either the A or B link for further instructions.

[Feel free to recommend improvements to the text or links in this template]

A - For a New Cluster use the following directions

Subpages format requires a metadata page.

Using the following instructions will complete the process of creating this article's subpages.

Click the blue "metadata template" link below to create the page.
On the edit page that appears paste in the article's title across from "pagename =".
You might also fill out the checklist part of the form. Ignore the rest.

For background, see Using the Subpages template Don't worry--you'll get the hang of it right away.
Remember to hit Save!

the "metadata template".

However, you can create articles without subpages. Just delete the {{subpages}} template from the top of this page and this prompt will disappear. :) Don't feel obligated to use subpages, it's more important that you write sentences, which you can always do without writing fancy code.

[Feel free to recommend improvements to the text or links in this template]

B - For a Cluster Move use the following directions

The metadata template should be moved to the new name as the first step. Please revert this move and start by using the Move Cluster link at the top left of the talk page.

The name prior to this move can be found at the following link.

[Feel free to recommend improvements to the text or links in this template]

[edit intro]

redirect Anticoagulant

References

External links

The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines

@@ Line 1: / Line 1: @@
 {{subpages}}
 {{editintro}}
-==Adverse effects==
+#redirect [[Anticoagulant]]
-Patients aged 80 years or more may be especially susceptible to bleeding complications with a rate of 13 bleeds per 100 person-years.<ref name="pmid17515465">{{cite journal |author=Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S |title=Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation |journal=Circulation |volume=115 |issue=21 |pages=2689-96 |year=2007 |pmid=17515465 |doi=10.1161/CIRCULATIONAHA.106.653048}}PMID 17515465</ref>
-Patients with cancer are more likely to have bleeding complications, especially if they have Stage III (regionally extensive) or IV (metastatic) cancer.<ref name="pmid12393647">{{cite journal |author=Prandoni P, Lensing AW, Piccioli A, ''et al'' |title=Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis |journal=Blood |volume=100 |issue=10 |pages=3484–8 |year=2002 |pmid=12393647 |doi=10.1182/blood-2002-01-0108}}</ref> Regardless of the extent of cancer, the risk of bleeding was less than the risk of recurrent [[embolism and thromboembolism]]:
-{| class="wikitable"
-|+ Rates of major bleeding and recurrent [[embolism and thromboembolism]] (VTE)
-! colspan="2" rowspan="2" |  !! rowspan="2"| No cancer !! colspan="3" |  Cancer
-|-
-!  Stage I or II !! Stage III !! Stage IV
-|-
-| rowspan="2"| '''Major<br>bleeding''' || Events per<br>100 patient-years ||align="center"| 8.6 || align="center"|3.4 ||align="center"| 19.1 ||align="center"| 42.8
-|-
-|      Hazard ratio ||align="center"| 1 ||align="center"| 0.5 ||align="center"| 2.15 ||align="center"| 4.8
-|-
-| rowspan="2"|  '''Recurrent<br>VTE''' || Events per<br>100 patient-years  ||align="center"| 12.8 ||align="center"| 14.5 ||align="center"| 44.1 ||align="center"| 54.1
-|-
-|     Hazard ratio ||align="center"| 1 ||align="center"| 1.9 ||align="center"| 5.3 ||align="center"| 4.6
-|-
-|   colspan="6" align="right"| Adapted from Table 3 of Prandoni et al.<ref name="pmid12393647"/>
-|}
 ==References==

Anticoagulation: Difference between revisions

Revision as of 05:54, 25 January 2008

A - For a New Cluster use the following directions

B - For a Cluster Move use the following directions

References

See also

External links

Navigation menu

Anticoagulation: Difference between revisions

Revision as of 05:54, 25 January 2008

A - For a New Cluster use the following directions

B - For a Cluster Move use the following directions

References

See also

External links

Navigation menu

Search